GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Earnings per Share (Diluted)

Kintara Therapeutics (STU:3DMA) Earnings per Share (Diluted) : €-2.02 (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Earnings per Share (Diluted)?

Kintara Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €-0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.02.

Kintara Therapeutics's EPS (Basic) for the three months ended in Jun. 2024 was €-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.02.

Kintara Therapeutics's EPS without NRI for the three months ended in Jun. 2024 was €-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.02.

During the past 3 years, the average EPS without NRIGrowth Rate was 81.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 64.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 24.90% per year.

During the past 13 years, Kintara Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 81.20% per year. The lowest was -426.70% per year. And the median was 26.70% per year.


Kintara Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Kintara Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Earnings per Share (Diluted) Chart

Kintara Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.63 -66.40 -24.41 -8.56 -0.30

Kintara Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.80 -1.72 -0.22 -0.05 -0.04

Competitive Comparison of Kintara Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Kintara Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's PE Ratio falls into.



Kintara Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Kintara Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2024 is calculated as

Diluted Earnings Per Share (A: Jun. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.729-0.168)/26.352
=-0.30

Kintara Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2024 is calculated as

Diluted Earnings Per Share (Q: Jun. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-2.159-0.002)/55.305
=-0.04

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Kintara Therapeutics  (STU:3DMA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kintara Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines